Services

Investment Highlights

Problem

• Developing medicines is extremely risky, expensive and time consuming.
• AI’s impact in drug discovery has not met market expectations.

Differentiation

• MAT simulates human physiology for rapid and more accurate novel target identification drug discovery, and drug development.
• Disease target(s) → de-risked drug candidates in months (vs years), saving hundreds of millions of dollars and greatly increasing likelihood of success.
• Predictive health data analysis for providers, payers, etc. – de-identified data enhances GATC’s drug discovery.

Proof

• MAT AI platform identifies compounds that would have beneficially affect human biology 11x better than current industry standards.
• AI validated through novel Opioid addiction therapy through animal trials at UC Irvine.
• 5 novel drug compounds discovered in 18 months – 8 more in discovery pipeline.